Nebius Groupの空売り状況は、投資家がNebius Groupの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Nebius Group (NASDAQ:NBIS) 株価情報, 空売り情報

Nebius Group

Nebius Group N.V. - Class A Ordinary Shares

Nebius Group NV is a tech company. It is a European provider of infrastructure and services to AI builders globally. The group builds full-stack infrastructure to service the growth of the AI industry, including the scale of GPU clusters, cloud platforms, tools, and services for developers. It has R&D hubs across Europe, North America and Israel.

Nebius Group NV

STRATA Skin Sciences, Inc.&nbsp;("STRATA" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSKN#NASDAQ">SSKN</a>), a medical technology company dedicated to advancing dermatologic care through innovation, announces that the American Medical Association (AMA) CPT Editorial Panel, in its May, 2025 summary of panel actions (<a href="https://www.globenewswire.com/Tracker?data=5HLUKvRJ509k_YOPLOkQaOOxUzetwEJ6Zpo2vtRH69p40WsMfW82FYzA7VgWlTo5OOLb501KmgsjBMojdHEQ8TyHgPWFz5C5RMZSMRwzWmoMDY17OrOZfiFfT7LcrEwY3RM0qrv2mMjbr7BmcHzobu4Yak5xTecakmyQbGs_XbmbwG3dMMwoi0X5DPS0hTvFOxkkuHWA9zhq9UxautPOmeOVxTv1dhZnjUEFh479Kqc=">May 2025: CPT&#xAE; Editorial Summary of Panel Actions &#x7C; AMA</a>) has accepted revision to CPT codes&nbsp;96920-96922, expanding reimbursement eligibility for excimer laser treatments to include multiple inflammatory and auto-immune skin conditions beyond their original psoriasis indication. This change reflects&nbsp;over 20 years&nbsp;of clinical evidence and real-world use of STRATA's&nbsp;XTRAC&#xAE; Excimer Lasers, a safe, effective, non-drug treatment for patients with chronic inflammatory and autoimmune skin diseases.
The updated CPT descriptor&nbsp;aligns&nbsp;the codes with current&nbsp;FDA clearances&nbsp;and commercial payer coverage guidelines. The changes are anticipated to&nbsp;reduce systemic denials and the need for prior authorizations. Further, the revised language now explicitly includes the treatment of inflammatory and autoimmune skin conditions, enabling coverage for&nbsp;conditions such as&nbsp;vitiligo, atopic dermatitis, mycosis fungoides, lichen planus, alopecia areata, and cutaneous T-cell lymphoma (CTCL). While currently with&nbsp;more than one million patients&nbsp;having been treated over the last 20 years, only&nbsp;30% of excimer laser procedures treat non-psoriasis conditions (based on 2023 Medicare data) as these require additional pre-authorization processing.&nbsp;&nbsp;
This change is expected to expand direct and clear reimbursement path and domestic market access from the roughly 10 million psoriasis patients covered today, to&nbsp;over 30 million potential patients, without the need to individually seek pre-determination of coverage.

News

SSKN

STRATA Skin Sciences Expands Reimbursement Eligibility For Excimer Laser Treatments To Include Multiple Inflammatory And Auto-Immune Skin Conditions Beyond Original Psoriasis Indication

<a href="https://www.globenewswire.com/Tracker?data=c7JNHSF7y2orGW9ttRlP7L3hfrD0exVLWd8UAXS7S3Fg9n9gbWSsubFtJD_AoY-9dBsPaZDmFGwCSz2a41Nsd7wpBWeJREzZ5bbH0xi9ozW3NCfp4NwTpHIB0oVweHaP">ITM Isotope Technologies Munich SE</a> (ITM), a leading radiopharmaceutical biotech company, and <a href="https://www.globenewswire.com/Tracker?data=RBqT9ZxON5OYXN1J2d81YmfmI9_6Bt-npo1PaxfHJZYjsXqWhZ5QGetN4qGUmlZUjWlVKplQyW4M8b0-ML1C0Mrp9D5lTZAVDbf-2L4ipJmIESOstXzgjBrSibOsIe0z">Radiopharm Theranostics</a> ((ASX:RAD, NASDAQ:<a href="https://www.benzinga.com/stock/RADX#NASDAQ">RADX</a>), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, today announced the signing of a supply agreement that will provide Radiopharm with ITM's medical radioisotope, non-carrier-added Lutetium-177 (n.c.a. 177Lu), to enable its usage in the clinical and potential future commercial development of the 177Lu-based molecules in Radiopharm's development pipeline.
Under the terms of the agreement, Radiopharm will use ITM's n.c.a. 177Lu across its clinical pipeline, including in key programs such as RAD 204 (PD-L1-targeting nanobody, Phase 1), RAD 202 (HER2-targeting nanobody, Phase 1), and RV01 (B7-H3-targeting monoclonal antibody, preclinical), for the treatment of solid tumors. Coupled with the targeting molecules that are designed to deliver ITM's n.c.a. 177Lu directly to tumor sites, the radioisotope emits therapeutic beta radiation with the aim to destroy malignant cells in a highly precise and localized manner.

RADX

ITM And Radiopharm Sign Supply Agreement For Non-Carrier-Added Lutetium-177 To Enable Usage In Clinical And Potential Future Commercial Development Of 177Lu-Based Molecules In Radiopharm's Development Pipeline

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19062116/Anjoy-0519-900x600-1.png" alt="" class="wp-image-13065" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19062116/Anjoy-0519-900x600-1.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19062116/Anjoy-0519-900x600-1-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19062116/Anjoy-0519-900x600-1-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
A Hong Kong listing plan by the leading maker of frozen foods like fish balls has received a green light from China's securities regulator
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul class="wp-block-list">
<li>The Chinese securities regulator has formally registered Anjoy Foods' plan to list in Hong Kong, which would complement its existing Shanghai listing</li>
<li>The frozen foods maker's revenue began to contract in the first quarter, and its gross margin is also notably lower than many other leading food companies</li>
</ul>
Hong Kong-based investors could soon have another option to taste, as frozen food specialist&nbsp;Anjoy Foods Group Co. Ltd.'s&nbsp;(603345.SH) planned IPO moves one step closer to reality after receiving approval from China's securities regulator.
The leading maker of frozen favorites like fish balls and steamed buns is in a race that has seen a growing number of companies with stocks traded on China's domestic A-share markets in Shanghai and Shenzhen making second listings in Hong Kong. In that regard, the company is vying with leading soy sauce and condiment maker&nbsp;Haitian Flavouring&nbsp;(603288.SH) to become China's first major food company with such a dual listing.
The recent rush of food stocks into Hong Kong is probably leaving investors a bit overwhelmed and trying to figure out which might offer the best returns. The list includes the likes of snack giants like&nbsp;<a href="https://thebambooworks.com/busy-ming-buzzes-investors-with-chinas-love-of-budget-snacks/">Busy Ming</a>,&nbsp;<a href="https://thebambooworks.com/three-squirrels-chases-hong-kong-listing-in-scurry-for-offshore-cash/">Three Squirrels</a>&nbsp;and&nbsp;<a href="https://thebambooworks.com/liuliu-offers-plum-investment-with-hong-kong-ipo-plan/">Liuli</a><a href="https://thebambooworks.com/three-squirrels-chases-hong-kong-listing-in-scurry-for-offshore-cash/">u</a>, which are trying to join&nbsp;Weilong Delicious&nbsp;(9985.HK), whose shares are already listed in Hong Kong. Then there are other food stalwarts like rice seller&nbsp;Shiyue Daotian&nbsp;(9676.HK), and instant noodle giants&nbsp;Uni-President China&nbsp;(0220.HK) and&nbsp;Tingyi&nbsp;(0322.HK).
Founded in 2001, Anjoy is somewhat differentiated from its peers by its apparent appetite for acquisitions, which have helped to fuel its growth. The company's portfolio includes a number of acquired brands, such as Honghu Temptation, Liuwu and Kung Fu Food. It made its latest acquisition just two months ago when it paid 445 million yuan ($62 million) for 70% of Ding Wei Tai, a maker of frozen seafood products like fish balls, the company revealed in&nbsp;<a href="https://static.sse.com.cn/disclosure/listedinfo/announcement/c/new/2025-04-29/603345_20250429_VWI5.pdf">first-quarter report&nbsp;</a>filed with the Shanghai Stock Exchange in April.
While its acquisitiveness might be a positive, the company is also distinguished by its relatively low gross margin compared with its peers, and also by the relatively low valuation for its Shanghai-listed stock. Part of the lower margin probably owes to the company's higher distribution costs, since its frozen products all require cold-chain delivery services.
Another turn-off for investors could be Anjoy's revenue, which began to contract this year.
Anjoy filed its Hong Kong listing application in January, boasting Goldman Sachs and leading Chinese investment bank CICC as its underwriters, indicating the listing is likely to raise more than $100 million. All Chinese companies listing in Hong Kong must get approval from the China Securities Regulatory Commission (CSRC), and Anjoy received such permission when the regulator formally announced its registration of Anjoy's application last Friday. According to the&nbsp;<a href="http://www.csrc.gov.cn/csrc/c105984/c7558562/content.shtml">announcement</a>, Anjoy plans to sell 59.5 million shares in the listing.
As we've already noted, Anjoy's Shanghai-listed stock is relatively undervalued compared to its peers, commanding a price-to-earnings (P/E) ratio of just 16. That's less than half the 36 for Haitian Flavouring's Shanghai-listed stock, and also well behind the 30 for Hong Kong-listed Weilong Delicious, 21 for Uni-President China and 18 for Tingyi. That seems to show that investors aren't so smitten with Anjoy's story, most likely due to its relatively low margins.
<h4 class="wp-block-heading">Shrinking revenue</h4>
With all that big-picture background in mind, we'll spend the second half of this review looking at Anjoy's financials that show how the company is a leader in China's large frozen food market, but is also a laggard in some key profitability metrics. Anjoy is China's largest quick-frozen food company with 6.2% of the market, according to third-party market data in its January&nbsp;<a href="https://www1.hkexnews.hk/app/sehk/2025/107101/documents/sehk25012000471.pdf">listing document</a>.
The company's top line revenue looked relatively solid when it filed for its IPO back in January, as it reported 7.7% growth during the first nine months of 2024. It finished out the year with similar growth, with the Shanghai-listed company&nbsp;<a href="https://static.sse.com.cn/disclosure/listedinfo/announcement/c/new/2025-04-29/603345_20250429_CNMT.pdf">reporting</a>&nbsp;its revenue grew 7.7% for the year to 15.1 billion yuan from 14 billion yuan in 2023.
But then the revenue began to contract in the first quarter of this year, falling 4.1% to 3.6 billion yuan from 3.75 billion yuan a year earlier, according to its first-quarter report. The company didn't provide any explanation for the sudden decline, though many companies reported similar weakness last year as Chinese consumer's reined in their spending with the nation's slowing economy.
The company breaks its product lines into three main areas, led by quick-frozen flavored and processed products like fish balls and pork sausage, which have accounted for about half of its revenue over the last three years. The second-largest category is quick-frozen prepared dishes like crayfish and egg dumplings, whose share of revenue has grown from 25% in 2022 to about 30% last year. The final category, quick-frozen flour and rice products like shumai and steamed buns, saw its share of Anjoy's revenue pie shrink from about 20% in 2022 to 16.5% last year.
The overall shrinking revenue is a tad worrisome, though not unexpected in the current environment. But less appetizing is Anjoy's relatively low gross margin of 23.3% last year. That was quite a bit lower than the 36% for Haitian in the first nine months of last year, and the roughly 33% for both Uni-President China and Tingyi. Part of that may owe to high distribution expenses, and it could also owe to difficulties integrating its numerous acquisitions. Whatever the cause, Anjoy will need to improve this important profitability metric if it wants to win over investors with a growing number of choices in food stocks.
Anjoy's profit rose by a slight 0.5% last year to 1.48 billion yuan, though the growth rate was well behind its revenue growth. And like its revenue, the company's profit also began to contract in the first quarter of this year, falling 10% to 395 million yuan, again, outpacing its rate of revenue decline.
At the end of the day, some investors may like Anjoy for its undisputed position as China's leading frozen food company. But with so many other choices, all with higher margins and stronger valuations, investors might require quite a bit of convincing to park their money in Anjoy's shopping cart.

Asia

Equities

IPOs

Opinion

US Delisting Risks Drive Chinese Food Companies To Hong Kong IPOs

JMP Securities analyst Aaron Hecht downgrades NexPoint Residential (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NXRT#NYSE">NXRT</a>) from Market Outperform to Market Perform.

Downgrades

Analyst Ratings

NXRT

JMP Securities Downgrades NexPoint Residential to Market Perform

ADTX

Aditxt Terminates Arrangement Agreement With Appili Therapeutics, Will Eliminate ~$16M In Closing Obligations

Vertiv Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>) on Monday announced its strategic alignment with Nvidia Corp.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) vision for AI data centers, specifically the deployment of 800 VDC power architectures.
Anticipating the demands of future AI deployments, including the NVIDIA Kyber and Rubin Ultra platforms, Vertiv&#8217;s comprehensive 800 VDC power portfolio is slated for release in the second half of 2026.
Aligning with NVIDIA&#8217;s AI roadmap, Vertiv plans to offer power/cooling ahead of each GPU generation for synchronized customer deployments in AI data centers (up to AI factories).
Also Read: <a target="_blank" href="https://www.benzinga.com//node/45459318" rel="noreferrer noopener">Chuck Schumer Blasts Trump For Backing AI Chip Sales To Saudi Arabia, UAE: &#8216;This Deal Could Very Well Be Dangerous&#8217;</a>
As AI rack power exceeds 300kW, Vertiv&#8217;s future 800 VDC portfolio (centralized rectifiers, efficient DC busways, rack DC-DC, DC backup) is expected to provide more efficient, lower-loss centralized power delivery, complementing their existing AC solutions.
Scott Armul, executive vice president of global portfolio and business units at Vertiv said, &#8220;As GPUs evolve to support increasingly complex AI applications at giga-watt scale, power and cooling providers need to be equally innovative to provide energy-efficient and high-density solutions for the AI factories.&#8221;
&#8220;We&#8217;ve spent decades deploying higher-voltage DC architectures across global telecom, industrial, and data center applications. We&#8217;re entering this transition from a position of strength and bringing real-world experience to meet the demands of the AI factory.&#8221;
In April, Vertiv reported first-quarter net sales of $2.04 billion, beating the consensus of&nbsp;$1.94 billion, and adjusted EPS stood at&nbsp;64 cents, <a target="_blank" href="https://www.benzinga.com/news/earnings/25/04/44953772/vertiv-raises-full-year-outlook-25-organic-sales-growth-fuels-strong-q1" rel="noreferrer noopener">beating&nbsp;the consensus of&nbsp;$0.62</a>.
Investors can gain exposure to the stock via Grizzle Growth ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DARP#NYSE">DARP</a>) and TCW Transform Systems ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWRD#NYSE">PWRD</a>).
Price Action: VRT shares are trading lower by 3.34% to $102.50 premarket at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com//node/45486440" target="_blank" rel="noreferrer noopener">David Sacks Hails Trump&#8217;s AI Strategy In Middle East As Power Move Over China — OpenAI CEO Sam Altman Backs Him: &#8216;Sorry Naive People Are Giving You Grief&#8217;</a></li>
</ul>
Image by T. Schneider via Shutterstock

Large Cap

Movers

Tech

DARP

NVDA

PWRD

Vertiv Develops Power Solutions In Sync With NVIDIA's AI Roadmap

Oxford Lane Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OXLC#NASDAQ">OXLC</a>) reported quarterly earnings of $0.23 per share which missed the analyst consensus estimate of $0.54 by 57.41 percent. This is a 34.29 percent decrease over earnings of $0.35 per share from the same period last year. The company reported quarterly sales of $121.20 million which missed the analyst consensus estimate of $224.45 million by 46.00 percent. This is a 46.73 percent increase over sales of $82.60 million the same period last year.

Earnings

Earnings Misses

OXLC

Oxford Lane Capital Q4 Adj. EPS $0.23 Misses $0.54 Estimate, Sales $121.20M Miss $224.45M Estimate

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>JP Morgan analyst Puneet Jain upgraded the rating for CI&amp;T Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CINT#NYSE">CINT</a>) from Neutral to Overweight and announced a $7 price target. CI&amp;T shares closed at $6.10 on Friday. <a href="https://www.benzinga.com/quote/cint/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Seth Sigman upgraded Williams-Sonoma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) from Underweight to Equal-Weight and raises the price target from $131 to $166. Williams-Sonoma shares closed at $173.84 on Friday. <a href="https://www.benzinga.com/quote/wsm/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Loop Capital analyst Alan Gould upgraded the rating for Charter Communications, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) from Hold to Buy and raised the price target from $430 to $510. Charter Communications shares closed at $427.25 on Friday. <a href="https://www.benzinga.com/quote/chtr/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Thomas Wadewitz upgraded United Airlines Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) from Neutral to Buy and raised the price target from $67 to $105. United Airlines shares closed at $77.93 on Friday. <a href="https://www.benzinga.com/quote/ual/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler analyst Charles Neivert upgraded the rating for AdvanSix Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASIX#NYSE">ASIX</a>) from Neutral to Overweight and raised the price target from $26 to $32. AdvanSix shares closed at $23.48 on Friday. <a href="https://www.benzinga.com/quote/asix/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying UAL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="610" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19080054/image-228-1024x610.png" alt="" class="wp-image-919700" style="width:656px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19080054/image-228-1024x610.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19080054/image-228-300x179.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19080054/image-228-768x458.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19080054/image-228.png 1128w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45490061/5-stock-picks-last-week-from-wall-streets-most-accurate-analysts-6">5 Stock Picks Last Week From Wall Street&#8217;s Most Accurate Analysts</a> </li>
</ul>
Photo via Shutterstock

Upgrades

Pre-Market Outlook

Markets

Trading Ideas

ASIX

CHTR

CINT

This United Airlines Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

<ul>
<li>Topline data expected by year end</li>
<li>Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects</li>
</ul>
ATLANTA, May 19, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=VEkdpKJV4MRsUpjLoBmDI7xj7fV9ZlZt-YilngazQukkkcBfK4YYoNKWUQAiSz1uhohWRRSJEBX_f7Hi8wq7caWnB69WEADnQ6w498t6diU=">Alzamend Neuro, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALZN#NASDAQ">ALZN</a>) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced the enrollment of the first patient of its first Phase II clinical study of AL001, in healthy human subjects. This study follows the successful development of a novel head coil by Tesla Dynamic Coils BV, a key component of the clinical trial.
In collaboration with Massachusetts General Hospital as its clinical trial site, Alzamend aims to explore the unique properties of AL001 and its potential to deliver lithium more effectively in the brain compared to marketed lithium salts. The study in healthy human subjects will serve as a baseline and assist Alzamend determine the best path forward in Alzheimer's, BD, MDD and PTSD patients by demonstrating AL001's targeted effectiveness and reduced systemic side effects. Previous studies in mice have shown that AL001 ensures better brain absorption while maintaining lower levels of lithium in the blood, paving the way for safer and more efficient treatments.

ALZN

Alzamend Neuro Enrolls First Patient Of First Phase II Clinical Study Of AL001, In Healthy Human Subjects; Topline Data Expected By Year End

Global Ship Lease (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSL#NYSE">GSL</a>) reported quarterly earnings of $2.65 per share which beat the analyst consensus estimate of $2.31 by 14.72 percent. This is a 4.74 percent increase over earnings of $2.53 per share from the same period last year. The company reported quarterly sales of $190.97 million which beat the analyst consensus estimate of $175.23 million by 8.98 percent. This is a 6.36 percent increase over sales of $179.56 million the same period last year.

Earnings Beats

Global Ship Lease Q1 Adj. EPS $2.65 Beats $2.31 Estimate, Sales $190.97M Beat $175.23M Estimate

During the last three months, 5 analysts shared their evaluations of Archer-Daniels-Midland (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>), revealing diverse outlooks from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $49.8, a high estimate of $60.00, and a low estimate of $45.00. Experiencing a 0.8% decline, the current average is now lower than the previous average price target of $50.20. 
<img src="https://www.benzinga.com/files/images/story/2025/1747656078_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Archer-Daniels-Midland among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manav Gupta</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$60.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Salvator Tiano</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$45.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Salvator Tiano</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$47.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Thomas Palmer</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$49.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Benjamin Theurer</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$48.00</td>
<td>$50.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Archer-Daniels-Midland. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Archer-Daniels-Midland compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Archer-Daniels-Midland's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Archer-Daniels-Midland's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ADM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Archer-Daniels-Midland analyst ratings.</a>
<h2>Delving into Archer-Daniels-Midland's Background</h2>
Archer-Daniels-Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. The company is also one of the largest grain merchandisers through its extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients and is a large producer of corn-based sweeteners, starches, and ethanol.
<h3>Unraveling the Financial Story of Archer-Daniels-Midland</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Negative Revenue Trend: Examining Archer-Daniels-Midland's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -7.65% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Consumer Staples sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Archer-Daniels-Midland's net margin is impressive, surpassing industry averages. With a net margin of 1.46%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Archer-Daniels-Midland's ROE excels beyond industry benchmarks, reaching 1.33%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Archer-Daniels-Midland's ROA stands out, surpassing industry averages. With an impressive ROA of 0.55%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a high debt-to-equity ratio of 0.56, Archer-Daniels-Midland faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 5 Analyst Ratings Have To Say About Archer-Daniels-Midland

Rivian Automotive Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) software chief Wassym Bensaid praised the Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rival's partnership with German Automaker Volkswagen AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/VWAGY#OTC">VWAGY</a>) as the company prepares to launch its budget EV.
What Happened: Bensaid said that the partnership has injected "start-up DNA" into Volkswagen, in an interview with Business Insider <a href="https://www.businessinsider.com/rivian-software-chief-vw-has-embraced-tesla-rivals-startup-dna-2025-5">on</a> Sunday.
"They were willing to adopt a much more agile, iterative, innovative approach to the entire development lifecycle, and keep the startup DNA that Rivian brings," Bensaid shared.
The report suggests Volkswagen had struggled to develop software to match the ones offered by new-generation automakers like Tesla, prior to its partnership with Rivian. The German automaker's lack of advanced software had resulted in a sales decline of over 10% last year in China, the report suggests.
Why It Matters: The two companies had <a href="https://www.benzinga.com/24/11/41934150/rivian-shares-rise-13-in-pre-market-after-volkswagen-increases-planned-investment-to-58b">announced a partnership </a>in November last year, in a deal worth over $5.8 billion. VW also announced plans to create a <a href="https://www.benzinga.com/news/25/03/44164768/volkswagens-new-budget-ev-will-rely-on-rivian-software-report">budget EV</a> dubbed the iD. EVERY 1, which will heavily leverage Rivian's software capabilities. The EV is said to be priced at almost $22,000.
VW says it plans on <a href="https://www.benzinga.com/25/02/43523277/volkswagen-unveils-plan-for-e20000-entry-level-electric-car">launching over nine </a>all-new EVs by the year 2027, as part of the collaboration with Rivian.&nbsp;
Elsewhere, Rivian CEO RJ Scaringe reiterated <a href="https://www.benzinga.com/news/25/05/45450269/whats-going-on-with-rivian-rivn-stock-15">the company's plans</a> for the Rivian R2, which could retail for $45,000 and launch sometime in the first half of 2026. The company also recently<a href="https://www.benzinga.com/25/05/45218458/rivian-handed-16-million-boost-by-government-as-plans-for-120-million-illinois-supplier-park-take-shape"> unveiled plans to expand</a> its Normal, Illinois production facility.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="191" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19072627/RIVN-MAY-19-2025-1024x191.jpg" alt="" class="wp-image-919627" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19072627/RIVN-MAY-19-2025-1024x191.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19072627/RIVN-MAY-19-2025-300x56.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19072627/RIVN-MAY-19-2025-768x143.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19072627/RIVN-MAY-19-2025-1536x286.jpg 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19072627/RIVN-MAY-19-2025.jpg 1653w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Rivian scores well on Momentum and Growth metrics, and has a satisfactory score on the Value metric. For more such insights, sign up for<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"> Benzinga Edge</a> today!
Check out more of Benzinga&#8217;s Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45487522/tesla-is-accepting-trade-ins-for-2024-cybertruck-amid-plummeting-sales-figures-report">Tesla Is Accepting Trade-Ins For 2024 Cybertruck Amid Plummeting Sales: Report</a></li>
</ul>
Photo: Shutterstock

RIVN

TSLA

VWAGY

Rivian's Software Chief Hails Volkswagen Partnership, Says German Automaker Gained 'Startup DNA' Ahead Of Budget EV Launch

5 analysts have shared their evaluations of Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Medtronic and provided 12-month price targets. The average target is $97.6, accompanied by a high estimate of $107.00 and a low estimate of $90.00. This upward trend is apparent, with the current average reflecting a 4.95% increase from the previous average price target of $93.00.
<img src="https://www.benzinga.com/files/images/story/2025/1747656061_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A clear picture of Medtronic's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$90.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$107.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$95.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$91.00</td>
<td>$90.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Medtronic. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Medtronic compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Medtronic's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Medtronic's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MDT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Medtronic analyst ratings.</a>
<h2>Get to Know Medtronic Better</h2>
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
<h3>Medtronic: A Financial Overview</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Positive Revenue Trend: Examining Medtronic's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 2.51% as of 31 January, 2025, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Medtronic's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 15.61% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Medtronic's ROE stands out, surpassing industry averages. With an impressive ROE of 2.64%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.44%, the company showcases effective utilization of assets.
Debt Management: Medtronic's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.54.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

5 Analysts Assess Medtronic: What You Need To Know

In the preceding three months, 8 analysts have released ratings for ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>), presenting a wide array of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $26.88, a high estimate of $32.00, and a low estimate of $20.00. Witnessing a positive shift, the current average has risen by 2.4% from the previous average price target of $26.25.
<img src="https://www.benzinga.com/files/images/story/2025/1747656047_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of ACADIA Pharmaceuticals by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$32.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$22.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$28.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$28.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$27.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$28.00</td>
<td>$28.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to ACADIA Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of ACADIA Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for ACADIA Pharmaceuticals's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of ACADIA Pharmaceuticals's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ACAD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on ACADIA Pharmaceuticals analyst ratings.</a>
<h2>About ACADIA Pharmaceuticals</h2>
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
<h3>A Deep Dive into ACADIA Pharmaceuticals's Financials</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: ACADIA Pharmaceuticals's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 18.7%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: ACADIA Pharmaceuticals's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 7.77%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): ACADIA Pharmaceuticals's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 2.53%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.64%, the company showcases effective utilization of assets.
Debt Management: ACADIA Pharmaceuticals's debt-to-equity ratio is below the industry average. With a ratio of 0.07, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACAD

Forecasting The Future: 8 Analyst Projections For ACADIA Pharmaceuticals

Across the recent three months, 18 analysts have shared their insights on Shake Shack (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHAK#NYSE">SHAK</a>), expressing a variety of opinions spanning from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Shake Shack, presenting an average target of $114.67, a high estimate of $154.00, and a low estimate of $85.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 8.54%. 
<img src="https://www.benzinga.com/files/images/story/2025/1747656032_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Shake Shack among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Charles</td>
<td>TD Securities</td>
<td>Maintains</td>
<td>Hold</td>
<td>$105.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Jake Bartlett</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$140.00</td>
<td>$134.00</td>
</tr>
<tr>
<td>John Ivankoe</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$100.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Brian Vaccaro</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$140.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>David Tarantino</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Andrew Charles</td>
<td>TD Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$105.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Dennis Geiger</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$100.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Jeffrey Bernstein</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Jake Bartlett</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$131.00</td>
<td>$154.00</td>
</tr>
<tr>
<td>Chris O'Cull</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$97.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Brian Bittner</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$125.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>David Tarantino</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Alton Stump</td>
<td>Loop Capital</td>
<td>Announces</td>
<td>Buy</td>
<td>$127.00</td>
<td>-</td>
</tr>
<tr>
<td>Anthony Trainor</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$95.00</td>
<td>-</td>
</tr>
<tr>
<td>John Ivankoe</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$105.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Jake Bartlett</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$154.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Nick Setyan</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$125.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Andrew Charles</td>
<td>TD Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$140.00</td>
<td>$140.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Shake Shack. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Shake Shack compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Shake Shack's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Shake Shack's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/SHAK/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Shake Shack analyst ratings.</a>
<h2>Unveiling the Story Behind Shake Shack</h2>
Shake Shack Inc is a roadside burger stand. It serves a classic American menu of premium burgers, hot dogs, crispy chicken, frozen custard, crinkle-cut fries, shakes, beer, wine and more. The company's burgers are made with a whole-muscle blend of all-natural, hormone and antibiotic-free Angus beef, ground fresh daily, cooked to order, and served on a non-genetically modified organism (GMO) potato bun. Its menu focuses on food and beverages, crafted from a range of classic American foods. The company serves draft Root Beer, seasonal freshly-squeezed lemonade, organic fresh brewed iced tea, cold brew coffee, organic apple juice, and Shack20 bottled water.
<h3>Key Indicators: Shake Shack's Financial Health</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Shake Shack displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 10.46%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.
Net Margin: Shake Shack's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 1.32%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 0.9%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Shake Shack's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.25%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.74.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SHAK

Forecasting The Future: 18 Analyst Projections For Shake Shack

Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) on Monday announced that it is now <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45486900/supermicro-now-accepting-orders-on-portfolio-of-more-than-20-systems-optimized-for-the-new-nvidia-" rel="noreferrer noopener">taking orders for</a> enterprise AI systems with&nbsp;Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) RTX PRO 6000 Blackwell Server Edition GPUs.
Supermicro&#8217;s suite of over 20 systems with&nbsp;RTX PRO Blackwell&nbsp;GPUs will significantly enhance performance for enterprise AI factory workloads. These include AI inference, AI development and model fine-tuning, generative AI, AI-driven graphics and rendering, video content and streaming, and game development.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45272331/super-micro-slides-as-ai-server-delays-nvidia-supply-limits-weigh-on-analyst-ratings" rel="noreferrer noopener">Super Micro Impacted By AI Server Delays And Nvidia Supply Limits, Analysts Lower Forecast</a>
Supermicro&nbsp;Nvidia-Certified&nbsp;Systems&nbsp;with RTX PRO 6000 Blackwell GPUs will serve as building blocks for&nbsp;Nvidia&nbsp;Enterprise AI Factory validated designs. They will integrate with&nbsp;Nvidia&nbsp;Spectrum-X networking, Nvidia-Certified Storage, and Nvidia AI Enterprise software&nbsp;to create full-stack solutions, accelerating the deployment of on-premises AI.
Supermicro offers more than 100 accelerated computing servers supporting Nvidia PCIe GPUs.
Supermicro&#8217;s all-new single-socket, GPU-optimized architecture based on the MGX reference design brings the inference capabilities of RTX PRO 6000 Blackwell GPUs closer to the edge.
Supermicro&#8217;s first MGX-based system leveraging a single-socket architecture, the new SYS-212GB-NR combines up to 4 latest-generation GPUs with balanced compute performance, resulting in a high-performing yet cost-effective edge AI solution.&nbsp;
By deploying Nvidia RTX PRO 6000 Blackwell GPUs, enterprises can reduce the number of servers required to support advanced AI edge inference, business intelligence and analytics, industrial automation, and retail applications, further reducing the cost of deploying AI at the edge.
Last week, Raymond James <a href="https://www.benzinga.com/markets/25/05/45399438/smci-rated-outperform-by-raymond-james-amid-dominance-in-branded-ai-server-market" target="_blank" rel="noreferrer noopener">initiated coverage on</a> Super Micro Computer, citing AI platforms constitute approximately 70% of Supermicro&#8217;s revenue, positioning it as a dominant player among branded server vendors. 
Raymond James highlighted that Supermicro has effectively carved out a niche for itself and &#8220;positioned itself in a sweet spot&#8221; between traditional branded IT vendors such as Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>), Hewlett Packard Enterprise (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) and contract manufacturers like&nbsp;Quanta.
Price Action: SMCI shares were trading lower by 3.81% to $44.39 premarket at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com//node/45483986" target="_blank" rel="noreferrer noopener">Apple Users Ditch Google Search, Trump Praises Nvidia&#8217;s Jensen Huang At Saudi Summit, SMCI Stock In &#8216;Sweet Spot&#8217; And More: This Week In Artificial Intelligence</a></li>
</ul>
Image via Shutterstock

DELL

SMCI

Super Micro Rolls Out AI Servers With Nvidia's Blackwell Chips To Cut Costs, Boost Performance

Easily representing one of the hottest investments in the post-pandemic landscape, tech juggernaut Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) stands at a critical crossroads. Mere days away from its<a href="https://www.benzinga.com/quote/NVDA/earnings"> first-quarter earnings report</a>, investors will be eager to see how management has negotiated the new economic paradigm under the Trump administration. At the same time, potentially bearish activity in the options market could be signaling broader apprehension.
So far this year, NVDA stock has barely moved above parity, a radical departure from the impressive rallies of prior years. However, in recent sessions, NVDA has come alive. In particular, the semiconductor giant is<a href="https://www.benzinga.com/media/25/05/45460918/jensen-huang-led-nvidia-plans-new-shanghai-research-hub-to-stay-competitive-in-china-as-us-export-curbs-threaten-ai-chip-sales-report"> expanding its research footprint</a> in China with a new Shanghai-based facility. The move symbolizes a strategic push to retain dominance in artificial intelligence in the region amid tightening U.S. export restrictions.
Earlier, NVDA stock also benefited from potentially thawing ties between the U.S. and China, with the two economic partners agreeing to a<a href="https://www.benzinga.com/trading-ideas/movers/25/05/45358653/nvidia-stock-surges-over-5-whats-going-on"> 90-day rollback of trade tariffs</a>. This deal marks a cessation in the aggressive posturing that has materialized since President Donald Trump's "Liberation Day" policy last month.
Notably, the tariffs have led to<a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45470155/consumer-sentiment-crashes-to-5-year-lows-as-inflation-fears-reach-1981-levels?utm_source=taboola&amp;utm_medium=exchange&amp;tblci=GiBHQ5jGSz2tTIA8W0d9W_RJMHgkmUPdKPzylaI48Ac4RiCN1Vcomc3V5NGfyeiJATDviEo#tblciGiBHQ5jGSz2tTIA8W0d9W_RJMHgkmUPdKPzylaI48Ac4RiCN1Vcomc3V5NGfyeiJATDviEo"> wide-ranging consequences</a>, particularly in terms of deflated consumer sentiment. Therefore, any meaningful signs of progress may lift market valuations.
At the same time, not everyone is convinced about the upward trajectory of NVDA stock. Last week, popular newsletter The Kobeissi Letter pointed to<a href="https://www.benzinga.com/markets/options/25/05/45460072/wall-street-getting-nervous-magnificent-7-giants-face-33m-bet-against-them-as-market-turbulence-looms"> rising put option volumes</a> among "Magnificent 7" stocks, of which Nvidia is a member. Since put options give holders the right (but not the obligation) to sell the underlying security at the listed strike price, the spike in volume raises eyebrows.
The Direxion ETFs: With the semiconductor specialist caught in a sentiment tug-of-war, this framework adds relevance for Direxion's NVDA-focused exchange-traded funds. Specifically, those who are optimistic may consider the Direxion Daily NVDA Bull 2X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDU#NASDAQ">NVDU</a>). On the other hand, the pessimists can try their luck with the Direxion Daily NVDA Bear 1X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDD#NASDAQ">NVDD</a>).
Primarily, the NVDU and NVDD ETFs offer a convenient mechanism for speculation. Typically, those who seek a leveraged bullish bet on NVDA stock or who want to short the security must engage the options market, which features myriad complexities. With Direxion ETFs, these units can be bought and sold like any other public security, thus easing the learning curve.
That said, the NVDU and NVDD products aren't without risks. Because of the volatility of leveraged funds, investors should approach these ETFs cautiously. Also, these funds should not be held for more than one day. Otherwise, the daily compounding effect may lead to positional erosion.
The NVDU ETF: Since the start of this year, the Direxion NVDA Bull 2X Shares has lost more than 20% of value. At the same time, a recent resurgence of momentum has buoyed the bulls' spirits.
<ul class="wp-block-list">
<li>In the past five sessions, NVDU gained over 22%, while in the trailing month, it's up more than 91%.</li>
<li>Currently, the 2X bull fund is creating a baseline below its 200-day moving average. Moving forward, the next obvious target is to break above $80.</li>
</ul>
<figure class="wp-block-image"><img loading="lazy" decoding="async" width="1032" height="626" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19075944/image-227.png" alt="" class="wp-image-919694" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19075944/image-227.png 1032w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19075944/image-227-300x182.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19075944/image-227-1024x621.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19075944/image-227-768x466.png 768w" sizes="(max-width: 1032px) 100vw, 1032px" /></figure>
The NVDD ETF: The Direxion NVDA Bear 1X Shares has also struggled this year, losing more than 15% since the January opener.
<ul class="wp-block-list">
<li>Sentiment for NVDD is a bit more problematic, with the inverse fund down more than 10% in the past five sessions.</li>
<li>NVDD is currently below the long-term support line represented at $5.80. Therefore, the ETF needs to pop above this level to avoid technical damage.</li>
</ul>
<figure class="wp-block-image"><img loading="lazy" decoding="async" width="1032" height="626" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19075944/image-227.png" alt="" class="wp-image-919695" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19075944/image-227.png 1032w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19075944/image-227-300x182.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19075944/image-227-1024x621.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19075944/image-227-768x466.png 768w" sizes="(max-width: 1032px) 100vw, 1032px" /></figure>
Featured image from <a href="https://www.shutterstock.com/image-photo/mining-crypto-currency-ethereum-online-money-1404536927">Shutterstock</a>

Long Ideas

Short Ideas

Technicals

ETFs

NVDD

NVDU

Sentiment Tug-Of-War Puts The Spotlight On Direxion's NVDA-Focused Bull And Bear Funds

Across the recent three months, 7 analysts have shared their insights on Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>), expressing a variety of opinions spanning from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $13.43, along with a high estimate of $20.00 and a low estimate of $7.00. A decline of 21.0% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1747656022_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A clear picture of Y-mAbs Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$11.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Nicole Germino</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$14.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Jeff Jones</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$20.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$12.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Alec Stranahan</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Nicole Germino</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$18.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Michael Ulz</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$7.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Y-mAbs Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Y-mAbs Therapeutics compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Y-mAbs Therapeutics's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Y-mAbs Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/YMAB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Y-mAbs Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Y-mAbs Therapeutics</h2>
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
<h3>Key Indicators: Y-mAbs Therapeutics's Financial Health</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Positive Revenue Trend: Examining Y-mAbs Therapeutics's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 13.41% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Y-mAbs Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -25.63% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -7.36%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Y-mAbs Therapeutics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -5.64%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

YMAB

What 7 Analyst Ratings Have To Say About Y-mAbs Therapeutics

Throughout the last three months, 24 analysts have evaluated Reddit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">10</td>
<td align="right">7</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Reddit, revealing an average target of $153.25, a high estimate of $220.00, and a low estimate of $75.00. Experiencing a 17.52% decline, the current average is now lower than the previous average price target of $185.81. 
<img src="https://www.benzinga.com/files/images/story/2025/1747656014_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A clear picture of Reddit's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$115.00</td>
<td>$168.00</td>
</tr>
<tr>
<td>Aaron Kessler</td>
<td>Seaport Global</td>
<td>Announces</td>
<td>Buy</td>
<td>$165.00</td>
<td>-</td>
</tr>
<tr>
<td>Ronald Josey</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$158.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$168.00</td>
<td>$158.00</td>
</tr>
<tr>
<td>Rohit Kulkarni</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Neutral</td>
<td>$130.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$140.00</td>
<td>$124.00</td>
</tr>
<tr>
<td>Michael Morris</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$165.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Naved Khan</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$220.00</td>
<td>$222.00</td>
</tr>
<tr>
<td>Thomas Champion</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$150.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$145.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Brian Nowak</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Ronald Josey</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$150.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$124.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Thomas Champion</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Justin Post</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$110.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$110.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Youssef Squali</td>
<td>Truist Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$150.00</td>
<td>-</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$158.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Devin Ryan</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$155.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$220.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Michael Morris</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$170.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>James Cordwell</td>
<td>Redburn Atlantic</td>
<td>Announces</td>
<td>Sell</td>
<td>$75.00</td>
<td>-</td>
</tr>
<tr>
<td>Josh Beck</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$200.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Thomas Champion</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$220.00</td>
<td>$210.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Reddit. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Reddit compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Reddit's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/RDDT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Reddit analyst ratings.</a>
<h2>Discovering Reddit: A Closer Look</h2>
Reddit is a social media platform where users can engage in conversations, explore, and create communities centered around their interests. Founded in 2005 by Steve Huffman and Alexis Ohanian, Reddit has evolved into a vast network of user-generated content organized into specialized forums known as "subreddits." The platform's unique community-driven model relies on volunteer moderators to manage content and maintain subreddit guidelines. Reddit generates revenue through advertising, Premium Memberships, and data licensing agreements.
<h3>Breaking Down Reddit's Financial Performance</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Positive Revenue Trend: Examining Reddit's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 61.49% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. When compared to others in the Communication Services sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Reddit's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 6.67%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Reddit's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 1.2%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Reddit's ROA excels beyond industry benchmarks, reaching 1.1%. This signifies efficient management of assets and strong financial health.
Debt Management: Reddit's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RDDT

The Analyst Verdict: Reddit In The Eyes Of 24 Experts

<a href="https://www.globenewswire.com/Tracker?data=WmlSh34TeEX9z46PfCSyVOkGV7yzBwKe88DEiOakC9zW0NoC_mtQEgUDA49Itx_kMeYku8o8x6raNYUQgoDMPSpM1Ye3Cl3v9G2K92AIHFo=">BIO-key International, Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKYI#NASDAQ">BKYI</a>), a global leader in Identity and Access Management (IAM) and biometric authentication solutions, is pleased to announce a strategic partnership with Cloud Distribution Co., a prominent Value-Added Distributor (VAD) headquartered in Saudi Arabia, with operations across the Middle East. Cloud Distribution joins BIO-key's Channel Alliance Partner (CAP) program to deliver BIO-key's full suite of IAM and biometric authentication solutions to enterprises and public institutions in Saudi Arabia, the UAE, and across the region. This partnership strengthens BIO-key's local capabilities while enabling Cloud Distribution to expand its cybersecurity portfolio with innovative, high-impact identity technologies.
As part of this strategic collaboration, Cloud Distribution Co. has committed dedicated in-country resources to support BIO-key's expansion in the region. A Pre-Sales Engineer, a Business Development Manager (BDM), and a Project Manager—based in Riyadh—will be part of Cloud Distribution's team fully focused on BIO-key. This investment reflects Cloud Distribution's clear bet on BIO-key's growth and long-term value in the Middle East market, ensuring local expertise, responsive support, and successful deployments.

Comments

Nebius Group

空売り

Nebius Group (NASDAQ:NBIS) 株価情報, 空売り情報

ニュース

パートナーシップ

ベンジンガ・グローバル